Profactor Pharma Ltd

An Midlothian company researching ground-breaking new haemophilia treatments has secured £1.1 million in investment to advance its R&D programme with the help of Kelvin Capital. ProFactor Pharma Ltd (PFP), based outside Edinburgh at the Easter Bush campus, has received the second tranche o

Kelvin Capital has led a £2m funding round for biotech business ProFactor Pharma to accelerate its work in developing a treatment for Haemophilia A. Kelvin Capital led the funding round, supported by Ingenza Ltd and the Scottish Investment Bank, the investment arm of Scottish Enterprise.